Logo Image
Opinion|Videos|July 22, 2024

The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.

Episodes in this series

Video content above is prompted by the following questions:

  • What is the important phase 3 data for the RSV vaccine that is leading the FDA to consider an expanded age range to 50-59?
  • How would RSV vaccine approval for adults aged 50-59 improve the clinical and economic impact of the disease?
    • What will the best practices be for identifying patients who are eligible for receiving the RSV vaccine with the potential updated indication?
  • How should payers adjust coverage decisions for RSV vaccines in patients aged 50-59 if this expanded indication is approved?
    • How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?

Related Content